AAV Vector Services
Adeno-associated virus (AAV) has become one of the most widely used vectors for gene delivery in both basic research and clinical gene therapy. Its unique combination of safety, stability, broad tropism, and long-term expression makes AAV an ideal vehicle for delivering therapeutic genes to targeted tissues.
AAVnerGene is pushing the boundaries of gene therapy with cutting-edge AAV technologies and solutions. Leveraging our team’s over 20 years extensive expertise, we provide comprehensive AAV vector services designed to accelerate research and therapeutic development. Our offerings include AAV vector design, AAV packaging and AAV characterization. With these services, AAVnerGene is committed to empowering researchers and biotech companies to drive innovation and achieve success in AAV gene therapy development.
AAV Vectors
An AAV vector is composed of two essential parts: (1) AAV Capsid: A protein shell built from viral capsid proteins (VP1/VP2/VP3) and (2) Internal Vector Genome: A synthetic DNA cassette packaged inside the capsid, flanked by the AAV ITRs. The capsid determines: tissue tropism, transduction efficiency and immune profile. The vector genome typically includes: two ITRs, Promoter/regulatory elements, Transgene or RNA payload (e.g., gene, shRNA, sgRNA), PolyA signal. Together, the capsid and genome define how the AAV behaves in vivo—its targeting, expression duration, and therapeutic potential.
Designing an effective AAV vector involves two fundamental steps: selecting the appropriate AAV capsid to achieve the desired tropism and delivery profile, and engineering the internal AAV genome to ensure precise, safe, and sustained transgene expression.
AAVnerGene provides comprehensive AAV vector design and AAV genomic optimization services, helping clients enhance AAV specificity, potency, and safety. Our experts guide the selection of appropriate AAV capsids, plasmid backbones, promoters, enhancers, and regulatory elements and labeling strategies to achieve precise transgene expression in target cells and tissues.
AAVnerGene delivers consistent, high-quality, and cost-effective AAV packaging services. Our proprietary AAV production systems (AAVone, AAVdual, AAVtri) allowing users to select the system that best fits their project requirements. Our proprietary transfection reagent, PEIone, together with the producer cell line HEK293one, enables highly efficient AAV vector production.
AAVnerGene offers a range of cell lines (HEK 293T, HEK 293, and HEK293one) for AAV vector production, both adherent and suspension, which allows researchers to choose the most suitable system for their production needs.
AAVnerGene provides iodixanol-based density gradients, cesium chloride (CsCl) based density gradients, and AAVx resin methods for AAV purification.
Our extensive experience with both common and engineered AAV capsids, combined with comprehensive AAV analytical technology, enables us to consistently deliver high-quality AAV vectors.
Short Turnaround
2 weeks for ≤ 5E13GC
Guaranteed Titer
≥1E13GC/mL (qPCR-SYBR)
High Full Particle
≥80% by Mass Photometry
Good Quality
≥95% Purity
Large Capacity
up to 1E17 GC
Multiple Systems
AAVone/AAVdual/AAVtri
Abundant Serotypes
>1000 AAV Capsids
Extensive Experience
>5,000 delivered AAV vectors
Experienced Support
>20 Years AAV Experts
We offer essential quality control testing, including vector genome titration, infectious titer assessment, AAV capsid purity and component analysis, as well as endotoxin and mycoplasma screening. In addition, our advanced services cover AAV genome identity and integrity verification, empty/full particle ratio measurement, and genomic impurity analysis. Our proprietary AAV-Q platform enables rapid, accurate, and highly sensitive potency testing (TCID50) as well as replication-competent AAV (rcAAV) assays with exceptional efficiency. Together, these comprehensive tests provide vital insights into vector quality and safety, helping customers choose the most suitable AAV vector for their applications.
|
FRET-based
biosensors |
FRET pair | Relative change of FRET ratio,ΔR/R (%) | Kd (μM) | Conditions used to measure ΔR/R and Kd | Substance (neurotransmitter or neuromodulator) | Template for sensing domain | In vivo use | References |
| SuperGluSnFR | ECFP-Citrine | 44 | 2.5 | Cultured neurons, 1P microscopy | Glutamate | GltI | Not tested | Hires et al., 2008 |
| M1-cam5 | ECFP-EYFP | 10 | Not determined | HEK293 cells, 1P microscopy | Acetylcholine | M1mAChR | Markovic et al., 2012 | |
| GlyFS | EGFP-Venus | 20 | 20 | Brain slices, 2P microscopy | Glycine | Atu2422 (AYW mutant) | Zhang et al., 2018 | |
| Single-FP-based biosensors | Circularly permuted FP | Relative change of fluorescence,ΔF/F (%) | Kd (μM) | Conditions used to measure ΔF/F and Kd | Substance (neurotransmitter or neuromodulator) | Template for sensing domain | In vivo use | References |
| iGluSnFR | cpGFP | 103 | 4.9 | Cultured neurons, 1P microscopy | Glutamate | GltI | Imaging of dendritic spines | Marvin et al., 2013 |
| SF-iGluSnFR A184V | sfGFP | 69 | 0.6 | Marvin et al., 2018 | ||||
| SF-iGluSnFR S72A | 250 | 34 | ||||||
| SF-Azurite-iGluSnFR | Azurite | 66 | 46 | |||||
| SF-Venus-iGluSnFR | Venus | 66 | 2 | |||||
| SF-mTurquoise2-iGluSnFR | mTurquoise | 90 | 41 | |||||
| iGABASnFR | sfGFP | 250 | 9 | Purified protein, fluorimeter | GABA | Pf622 | Imaging of single neurons | Marvin et al., 2019 |
| iGluf | EGFP | 100 | 137 | HEK293 cells, stopped-flow | Glutamate | GltI | Not tested | Helassa et al., 2018 |
| iGluu | 170 | 600 | ||||||
| R-iGluSnFR1 | mApple | −33 | 11 | Purified protein, fluorimeter | Wu et al., 2018 | |||
| R-ncp-iGluSnFR1 | 0.9 | |||||||
| GACh | EGFP | 90 | 2 | HEK293 cells, 1P microscopy | Acetylcholine | M3R | Imaging of single neurons | Jing et al., 2018 |
| GRABNE1m | 230 | 1.9 | Norepinephrine | α2AR | Aggregated fluorescence signal | Feng et al., 2019 | ||
| GRABNE1h | 150 | 0.093 | ||||||
| Nb80-GFP | Not determined | Not determined | Not applicable | β2AR/Nb80 | Not tested | Irannejad et al., 2013 | ||
| OR-sensor | EGFP | Not determined | Not determined | Not applicable | Activation of μ and δ ORs | μ and δ ORs/Nb33 | Not tested | Stoeber et al., 2018 |
| iATPSnFR | spGFP | 150 | 630 | Cultured neurons, 1P microscopy | ATP | ε subunit of FOF1 ATPase from Bacillus PS3 | Imaging of single astrocytes | Lobas et al., 2018 |
| dLight1.1 | EGFP | 230 | 0.33 | HEK293 cells, 1P microscopy | Dopamine | DRD1 (inserted into the ICL3) | Aggregated fluorescence signal | Patriarchi et al., 2018 |
| dLight1.2 | 340 | 0.77 | ||||||
| DA1m | 90 | 0.13 | DRD2 (inserted into the ICL3) | Sun et al., 2018 | ||||
| DA1h | 0.01 | |||||||